Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer

Clinical Cancer Research

Volumn 10, Issue 10, 2004, Pages 3438-3443

  Staalesen, Vidar ^a,b   Leirvaag, Beryl ^a,b   Lillehaug, Johan Richard ^b   Lønning, Per Eystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA; DOXORUBICIN; FLUOROURACIL; MITOMYCIN; PROTEIN P21; PROTEIN P21B; PROTEIN P53; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RESISTANCE; CANCER RISK; CONTROLLED STUDY; EPIGENETICS; GENE MUTATION; GENE SILENCING; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHYLATION; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CLONING, MOLECULAR; DNA METHYLATION; DNA PRIMERS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MITOMYCIN; MODELS, GENETIC; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS P21(RAS); RAP GTP-BINDING PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2542465850     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0796     Document Type: Article

References (57)

1. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond) 1993;362:847-9.
2. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992;89:9210-4.
3. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis (Lond) 2000;21:485-95.
4. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16(INK4a) contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
5. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;55:64-75.
6. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187:127-37.
7. Lowe SW, Bodis S, Mcclatchey A, et al. P53 status and the efficacy of cancer-therapy in-vivo. Science (Wash DC) 1994;266:807-10.
8. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
9. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6.
10. Geisler S, Børresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-4.
11. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
12. Lønning P. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol 2003;4:177-85.
13. Aas T, Geisler S, Eide GE, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003;39:438-46.
14. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55:28-37.
15. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent Cdk and PCNA binding domains in P21(Cip1). Nature (Lond) 1995;375:159-61.
16. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P. Mice lacking P21(C/P1/Waf1) undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
17. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell-cycle arrest compromised by P21 deficiency. Nature (Lond) 1995;377:552-7.
18. Dulic V, Kaufmann WK, Wilson SJ, et al. P53-dependent inhibition of cyclin-dependent kinase-activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-23.
19. Cheng MG, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571-83.
20. Gu Y, Turck CW, Morgan DO. Inhibition of Cdk2 activity in-vivo by an associated 20k regulatory subunit. Nature (Lond) 1993;366:707-10.
21. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The P21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
22. Sherr CJ, Roberts JM. Inhibitors of mammalian G(1) cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
23. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G(1)-phase progression. Genes Dev 1999;13:1501-12.
24. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinases. Nature (Lond) 1993;366:701-4.
25. Dulic V, Stein GH, Far DF, Reed SI. Nuclear accumulation of p21(Cip1) the onset of mitosis: a role at the G(2)/M-phase transition. Mol Cell Biol 1998;18:546-57.
26. Medema RH, Klompmaker R, Smits VAJ, Rijksen G. p21(waf1) can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 1998;16:431-41.
27. Niculescu AB, Chen XB, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21(Cip1/Waf1) at both the G(1)/S and the G(2)/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998;18:629-43.
28. Nozell S, Chen X. p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family. Oncogene 2002;21:1285-94.
29. Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21(WAF1) promoter region. Cancer Res 2000;60:3290-8.
30. Ellis PA, Lonning PE, Borresen-Dale A, et al. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer 1997;76:480-5.
31. Terry LA, Boyd J, Alcorta D, et al. Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines. Mol Carcinog 1996;16:221-8.
32. Koopmann J, Maintz D, Schild S, et al. Multiple polymorphisms, but no mutations, in the Waf1/Cip1 gene in human brain-tumors. Br J Cancer 1995;72:1230-3.
33. Li YJ, Laurentpuig P, Salmon RJ, Thomas G, Hamelin R. Polymorphisms and probable lack of mutation in the Waf1-Cip1 gene in colorectal-cancer. Oncogene 1995;10:599-601.
34. Konishi R, Sakatani S, Kiyokane K, Suzuki K. Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors. J Dermatol Sci 2000;24:177-83.
35. Li YJ, Khe HX, Zhou XP, et al. Analysis of the p21 gene in gliomas. J Neurooncol 1998;40:107-11.
36. Claassen GF, Hann SR. A role for transcriptional repression of p21(CIP1) by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci USA 2000;97:9498-503.
37. Wu SQ, Cetinkaya C, Munoz-Alonso MJ, et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003;22:351-60.
38. Amati B. Integrating Myc and TGF-beta signalling in cell-cycle control. Nat Cell Biol 2001;3:E112-3.
39. Chin YE, Kitagawa M, Su WCS, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1. Science (Wash DC) 1996;272:719-22.
40. Estanyol JM, Jaumot M, Casanovas O, et al. The protein SET regulates the inhibitory effect of p21(Cip1) cyclin E-cyclin-dependent kinase 2 activity. J Biol Chem 1999;274:33161-5.
41. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.
42. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
43. Loden M, Sfighall M, Nielsen NH, et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002;21:4680-90.
44. Lonning PE. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol Med 2004;10:113-8.
45. Balbin M, Hannon GJ, Pendas AM, et al. Functional analysis of a p21(WAF1,CIP1,SDI1) mutant (Arg(94)→Trp) identified in a human breast carcinoma-evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J Biol Chem 1996;271:15782-6.
46. McKenzie KE, Siva A, Maier S, Runnebaum IB, Seshadri R, Sukumar S. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin Cancer Res 1997;3:1669-73.
47. Facher EA, Becich MJ, Deka A, Law JC. Association between human cancer and two polymorphisms occurring together in the p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene. Cancer (Phila) 1997;79:2424-9.
48. Furutani M, Arii S, Tanaka H, et al. Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. Cancer Lett 1997;111:191-7.
49. Gao X, Chen YQ, Wu N, et al. Somatic mutations of the Waf1/Cip1 gene in primary prostate-cancer. Oncogene 1995;11:1395-8.
50. Ibrahim SO, Lillehaug JR, Dolphine O, Johnson NW, Wamakulasuriya KA, Vasstrand EN. Mutations of the cell cycle arrest gene p21 (WAF1), but not the metastasis-inducing gene S100A4, are frequent in oral squamous cell carcinomas from Sudanese toombak dippers and non-snuff-dippers from the Sudan, Scandinavia, USA and UK. Anticancer Res 2002;22:1445-51.
51. Iida S, Fujii H, Mofiwaki K. A somatic mutation of the p21 ((Waf1/Cip1)) gene in a human adrenocortical adenoma. Anticancer Res 1997;17:633-6.
52. Lacombe L, Orlow I, Silver D, et al. Analysis of p21(WAF1/CIP1) in primary bladder tumors. Oncol Res 1996;8:409-14.
53. Patino-Garcia A, Sotillo-Pineiro E, Sierrasesumaga-Ariznabarreta L. p21WAF1 mutation is not a predominant alteration in pediatric bone tumors. Pediatr Res 1998;43:393-5.
54. Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V, Ohnishi T. Polymorphism of the WAF1 gene is related to susceptibility to cervical cancer in Japanese women. Int J Mol Medi 2001;7:261-4.
55. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21(WAF1/CIP1) polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 2000;91:9-15.
56. Tsai MH, Chen WC, Tsai FJ. Correlation of p21 gene codon 31 polymorphism and TNF-alpha gene polymorphism with nasopharyngeal carcinoma. J Clin Lab Anal 2002;16:146-50.
57. Hsieh YY, Tsai FJ, Chang CC, et al. p21 gene codon 31 arginine/serine polymorphism: non-association with endometriosis. J Clin Lab Anal 2001;15:184-7.